Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

williams & halls ehf. - pemetrexedum dínatríum - stofn fyrir innrennslisþykkni, lausn - 500 mg

Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

williams & halls ehf. - pemetrexedum inn - innrennslisþykkni, lausn - 25 mg/ml

Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

bayer ab* - norethisteronum inn - tafla - 5 mg

Uniunea Europeană - islandeză - EMA (European Medicines Agency)

roche registration gmbh - cobimetinib hemifumarat - melanoma - Æxlishemjandi lyf - cotellic er ætlað til notkunar í samsettri meðferð með vemurafenibi til meðferðar hjá fullorðnum sjúklingum með sortuæxli sem ekki er hægt að meðhöndla með braf v600 stökkbreytingum.

Uniunea Europeană - islandeză - EMA (European Medicines Agency)

secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - Æxlishemjandi lyf - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies.  follicular lymphoma (fl) that is refractory to at least two prior  systemic therapies.

Uniunea Europeană - islandeză - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - Æxlishemjandi lyf - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Uniunea Europeană - islandeză - EMA (European Medicines Agency)

amgen europe bv - sotorasib - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - alprostadilum inn - stungulyfsstofn og leysir, lausn - 10 míkróg

Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - alprostadilum inn - stungulyfsstofn og leysir, lausn - 20 míkróg

Islanda - islandeză - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - finasteridum inn - filmuhúðuð tafla - 5 mg